1	Dynamics of the SARS-CoV-2 epidemic in the earliest-affected areas in Italy:
2	Mass screening for SARS-CoV-2 serological positivity (SARS-2-SCREEN).
3	Gabriele Paganii, Dario Bernacchiai, Federico Contii, Andrea Giacomellii, Rossana
4	Rondanin ₆ , Vittore Scolari ₅ , Patrizia Boracchi ₄ , Cecilia Eugenia Gandolfi ₂ Silvana Castaldi _{2,3} ,
5	Elia Biganzoli4*, Massimo Galli1*.
6	
7	1: Department of Clinical and Biomedical Sciences (DIBIC) "L. Sacco", University of Milan, Italy
8	2: Post graduate School in Public Health Dept Biomedical Sciences for Health, University of Milan, Italy
9 10	3: Fondazione IRCCS Ca' Granda Ospedale Maggiore policlinico di Milano, Italy
10 11	4: Department of Clinical Sciences and Community Health & DSRC, University of Milan, Italy. 5: Institut Curie-PSL Research University, CNRS, Sorbonne Université, UMR3664, F-75005, Paris, France.
12	6: Medispa s.r.l.
13	
14	*Equally contributing Authors
15	
16	
17	
18	
19	
20	Corresponding Authors:
21	Gabriele Pagani
22	gabriele.pagani@unimi.it
23	ASST FBF-Sacco, Infectious Diseases Dep., III Division
24	Luigi Sacco Hospital
25	Via G.B. Grassi 74, 20157
26	Milan, Italy
27	
28	Cecilia Eugenia Gandolfi
29	cecilia.gandolfi@unimi.it
30	Department of Biomedical Sciences for Health
31	University of Milan
32	Via C. Pascal 36, 20133
33	Milan, Italy
34	

35 ABSTRACT

Background Several municipalities in the Lombardy Region have been affected by the SARS-CoV-2 infection since the earliest stages of the epidemic. To date, 89442 confirmed cases have been diagnosed in Lombardy, and mortality in several municipalities has already surpassed that of the past decade. Currently, the true extent of the SARS-CoV-2 infection remains unknown as several affected subjects may have been asymptomatic or have presented mild disease, thus not resulting in the identified COVID-19 cases.

42 Methods This cross-sectional study aims to define the spread of infection within the population 43 by determining the seroprevalence of IgG antibodies directed against SARS-CoV-2 by rapid 44 immunochromatographic testing and subsequent confirmation by serology on venous blood by 45 liquid phase immunochemical testing, also allowing to compare the two methods. Testing will 46 be performed on adults and minors residing, domiciled or working in several municipalities of 47 the Lombardy Region, involved in the initial stages of the epidemic. The study will include 48 rapid finger-prick testing and venous sampling for antibodies against SARS-CoV-2, and 49 nasopharyngeal swabbing (NPS). Concurrent notification of test results will occur via the 50 regional healthcare information system (SISS).

51 **Discussion** This study was developed with the desire to understand the seroprevalence of 52 SARS-CoV-2 infection and the epidemiological transmission characteristics of this virus. 53 Understanding the spread and severity of the disease could help in the implementation of 54 effective infection surveillance containment and countermeasures facilitating the identification 55 of cases that have been exposed to the virus and the traceability of contacts.

56 This study has been approved by the Ethics Committee of the University of Milan 57 (35/2020).

59	Keywords:	SARS-CoV-2,	coronavirus,	COVID-19,	antibodies,	prevalence,	rapid	test,
60	immunocron	natographic test.						
61								
62								
63								
64								
65								
66								
67								
68								
69								
70								
71								
72								
73								
74								
75								
76								
77								
78								
79								
80								
81								
82								
83								

84 BACKGROUND

85

86 Several municipalities of the Lombardy Region have been affected by the Severe Acute 87 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection since the earliest stages of the 88 epidemic. In fact, the first so called "red zone", a quarantined area where all movements were 89 restricted, was established in the Lodi province (south-eastern Lombardy) on the 23rd of 90 February, following the first Coronavirus Induced Disease (COVID-19) hospitalization from 91 Codogno (LO). 92 To date, a total of 89442 SARS-CoV-2 cases have been confirmed in the Lombardy Region, 93 however the true extent of the SARS-CoV-2 infection remains unknown. In particular, the 94 number of infected subjects having presented minimal or no symptomatology has not been

95 precisely determined.

96 The World Health Organization (WHO) recognized the existence of a coronavirus responsible 97 for pneumonia in Wuhan, China on December 29th 2019₂. This virus, initially identified as n-98 CoV-2019 (novel Coronavirus 2019), was subsequently referred to as SARS-CoV-2, and its 99 clinical manifestations known as Coronavirus Induced Disease 2019 (COVID-19). The 100 pandemic was declared on March 11th 2020₃.

101 Currently, the WHO considers forwarding scientific knowledge on mass screening essential for 102 the battle against the spread of SARS-CoV-2, in order to allow better understanding and 103 planning of current and future containment policies.

All countries that have made extensive use of diagnostic testing on the whole population, regardless of presence or absence of symptoms, have achieved a drastic drop in infection and spread₄.

To date, the only diagnostic tool to be officially recognized by the Italian Ministry of Health
 for SARS-CoV-2 infection is the NPS, that uses real-time reverse transcription polymerase

chain reaction (rRT-PCR) to identify and amplify traces of the SARS-CoV-2 genome within a
patient's samples. This diagnostic method has several limits, including high costs, long
complete analysis times, and many false negatives (low diagnostic sensitivity).

Alongside the diagnostic aspect, the development of knowledge regarding disease spread and prevalence in the population will become increasingly important in the near future. For this reason, the development of research on seroprevalence with appropriate methods is of fundamental importance.

This study was developed with the desire to understand the seroprevalence of SARS-CoV-2 infection and the epidemiological transmission characteristics of this virus in the earliest affected areas in Italy. Understanding the spread and severity of the disease could help in the implementation of effective infection surveillance containment and countermeasures facilitating the identification of cases that have been exposed to the virus and the traceability of contacts.

122

123 METHODS & DESIGN

The primary objective of this cross-sectional study is to determine the spread of infection within the population by determining the seroprevalence of IgG antibodies directed against SARS-CoV-2 by rapid immunochromatographic testing and subsequent confirmation by serology on venous blood by liquid phase immunochemical testing.

Secondary objectives include comparing IgG and IgM antibody positivity obtained by rapid testing via direct viral research to serological data obtained by the immunochemical method. We also aim to establish a database for future prospective projects eg. serial antibody titer assessed over time, possibly expanding the study to several municipalities particularly affected by the SARS-CoV-2 epidemic around the Lombardy region. This may help localize and isolate possible current and future outbreaks. For the municipalities included in first so-called "red zone", thus more severely hit, we hypothesize a seroprevalence of IgG antibodies directed against SARS-CoV-2 between 30% and 50%, due to probable unrestricted viral circulation in the days or weeks before the first hospitalized case. For the other, less severely affected, municipalities we estimate a prevalence between 10 and 30%.

139 According to current regional legislation (DGR n. XI/3114 and DGR n. XI/3131) during the 140 second phase of the epidemic, NPS will be performed in all symptomatic individuals, flagged 141 as "suspect COVID-19 cases" by their family doctor, and in all traced contacts prior to 142 readmission in society. Although rRT-PCR on NPS is the current gold standard diagnostic test 143 for SARS-CoV-2, diagnostic accuracy depends on several pre-analytical and analytical 144 variables, and many patients can be asymptomatic (thus currently will not receive testing in the 145 Lombardy region). The measurement of specific COVID-19 antibodies could serve as an 146 additional tool for disease detection and management, playing a potential key role in 147 surveillance and screening. The latter may be even more advantageous if implemented in the 148 form of rapid finger-prick testing. In fact, as mentioned above, one of our secondary objectives 149 is the comparison of IgG and IgM antibody positivity obtained by rapid testing, to serological 150 data obtained by the immunochemical method. We hypothesize that antibody detection by rapid 151 finger-prick testing will be non-inferior to detection by venous sampling.

152 Testing will be performed at specific locations in the various municipalities, equipped with the153 following rooms:

154 155 • A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks).

• A room for collection of personal data and for carrying out rapid tests.

• A room for the execution of venous blood samples.

• A room for carrying out NPS.

- A room for the dressing and undressing of healthcare workers.
- A storage room with refrigerator.
- 161
- 162 Inclusion and exclusion criteria
- 163 All following subjects may be included in the study:
- The entire adult population living in the municipality, including residential care
 facilities.
- All individuals over 18 who were present in the municipality on a daily basis for work
 reasons during the epidemic eg. law enforcement officers, traders, workers in local
 companies etc.
- 169 3. All minors residing and/or domiciled in the municipality, upon explicit
 170 parental/guardian request.
- An absolute exclusion criterion is represented by being quarantined. However, data regardingquarantine will be taken into account for defining the dynamics of the epidemic.
- 173
- 174 **Population follow-up and counseling**
- Individuals with **negative** results to rapid testing who do not present symptoms
 suggestive for acute infection will be sent home, after counseling on appropriate
 behaviors aimed at avoiding infection.
- 178
 2. Individuals with negative results to rapid testing who, however, present symptoms
 179 suggestive for acute infection will be evaluated by medical personnel to determine the
 180 need for further investigations (imaging or ER access) and quarantined, at home or in a
 181 different location if home is deemed unsuitable, pending swab results. These individuals
 182 will receive extensive counseling on best-practices during the quarantine period.

- Individuals with positive results to IgM rapid testing, regardless of IgG results, will be
 quarantined at home, or in a different location if home is deemed unsuitable, pending
 swab results. If swab results are also positive, quarantine will be confirmed and
 extended and counseling on best-practices during the quarantine period will be
 provided.
- 188
 4. Individuals with **positive** results to IgG rapid testing only will be sent home, without
 189
 need for fiduciary quarantine.
- 190 5. Quarantined individuals will be provided with pulse oximeter, surgical masks and
 191 extensive counseling on best-practices during the quarantine period.
- 6. All swab positive individuals, regardless of rapid test results, will be notified to local
 health authorities using a specific infectious disease digital notification platform for the
 Lombardy Region. The swab positive individual will thus be quarantined, and followup will be carried out by the local health authorities, as indicated in current regional
 protocols.

197

198 **Results reporting**

Rapid test results will be communicated in real time and a full report comprising collected
anamnestic and epidemiological data, and rapid test results will be emailed or printed, according
to patient preference.

- 202 NPS results will be communicated as follows:
- In case of a negative result, attending medical personnel will call the patient directly.
- In case of a positive result, attending medical personnel will call the patient's family
 doctor, who will then notify the local health authorities via the regional infectious
 disease digital notification platform, and communicate the positive result to the patient.

208 Sample management

- Rapid tests will be analyzed by assigned staff within the timeframe suggested by the manufacturer and will then be suitably disposed of by the same staff (biohazardous waste).
- 2. Venous blood samples will be stored on site, refrigerated at +4°C, and transported to
 the lab for analysis, daily.
- 3. Swabs will be stored on site, refrigerated at +4°C, and transported to the lab for analysis,
 daily (or within 48 hours during the weekend). NPSs are placed in a triple container
 during transportation: the collection tube is placed in a conical tube ("falcon" type tube),
- and then in a spill proof box.
- 218

219 Sampling plan and determination of sample size

For the purposes of the primary objective of the study, random sampling will be carried out from the municipal registry list, stratifying by gender and conventional age classes (0-19; 20-39; 40-59; >=60). At present, geographical stratification does not seem necessary given the homogenous distribution of cases identified to date. Confirmed cases that have already been identified in the municipality must be included in the study sample with the same probability as other subjects. In fact, the rapid test and venous sample seroprevalence results on previously confirmed cases will provide further data useful for comparison.

A sample size of 355 subjects from a population of 4616 individuals provides a bilateral 95% confidence interval with an accuracy (half-amplitude) of 0.05 when actual prevalence is close to 0.56. In case of higher or lower prevalence, the sample size decreases to 302 subjects in case of prevalence equaling 0.3, very close to current estimates, and to 234 subjects in case of a more skeptical prevalence hypothesis of 0.8. Considering the largest population sample combined to a possible 20% drop-out, sample size increases to 444 subjects. Assuming an infinite population_{7,8}, sample size would be determined at 402 subjects, to be increased to 503 subjects considering 20% drop-out. Thus, a sample size of around 500 subjects would seem reasonable for the main study objective.

Regarding the secondary objective, relating to sensitivity and specificity of the rapid test compared to the gold-standard on venous blood samples, the sample size required for a bilateral 95% confidence interval with a maximum amplitude of 0.1, is 527 subjects for sensitivity and 438 subjects for specificity, assuming a prevalence of 0.3 with optimal sensitivity and specificity equal to 0.9. Thus, in order for both confidence intervals to have a maximum amplitude of 0.1, the largest of the two sample sizes (527 subjects) must be chosen. Also, sample size should be further increased to 659 subjects to allow for 20% drop-out.

Accordingly, in case of hypothesized sensitivity and specificity values equal to 0.8, the sample size should be increased to 880 subjects, and to 1100 subjects to include 20% drop-out.

However, in an optimal situation, the sample size required for the secondary objective appears compatible with that needed for the primary objective. In fact, a study that could effectively recruit at least 500 people would continue to offer expected amplitudes of confidence intervals up to 0.144 for sensitivity and <0.1 for specificity, even in conditions of lower diagnostic performance, always hypothesizing a prevalence of 0.3.

250 Sample size calculations were carried out using PASS v. 16.0.3 validated software.

251

252 **DISCUSSION**

253 Location and testing procedures

Testing will be performed at various locations in the selected municipalities, equipped with thefollowing rooms:

• A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly

spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks).

258	• A room for collection of personal data and performing rapid tests.
259	• A room for the execution of venous blood samples.
260	• A room for carrying out NPS.
261	• A room for the dressing and undressing of healthcare workers.
262	• A storage room with refrigerator.
263	Separate paths will be defined for the entrance and exit of tested subjects, particularly to prevent
264	loitering between individuals waiting to be tested and those already tested, as well as to prevent
265	large gatherings in confined spaces like corridors, making social distancing impracticable.
266	
267	Subjects are tested as follows:
268	1. Assembly of up to 10 people every 30 minutes to be examined according to geographical
269	location. Participation in the study is voluntary. Those called upon must be equipped
270	with a correctly worn surgical mask. Security personnel will be assigned to ensure
271	correct use of PPE and compliance with safety distance.
272	2. Acquisition of informed consent.
273	3. Rapid testing for antibodies against SARS-CoV-2 in all individuals in the assembled
274	group.
275	4. Anamnestic and personal data collection on a local network electronic database and
276	printing of labels for sample identification.
277	5. Venous blood sampling in all those resulting positive to the rapid test and, at random,
278	in a proportion of negative subjects, still to be determined.
279	6. Swabbing of all individuals resulting positive to the rapid test, all people with recent
280	history of symptoms compatible with COVID-19, and in a proportion of negative
281	subjects, yet to be determined, chosen at random.

Given that examining the largest number of people in the shortest time possible is of paramount importance in a cross-sectional study, we decided to perform rapid testing as the first procedure, and to gather epidemiological and anamnestic data while waiting for the appropriate reading time (10 to 20 minutes). This will enable us to perform between 200 and 250 rapid tests per day.

287

288 **Personnel protection measures**

Seeing as the SARS-CoV-2 epidemic is still active in the Lombardy region, participant and personnel safety will be a main concern. Personal protective equipment (PPE) and sanitization of all rooms and equipment will be guaranteed for the all duration of the study.

All patients must be equipped with a correctly worn surgical mask and disposable gloves.

293 PPE will be provided according to personnel role, as follows:

- Surgical mask and disposable gown for personnel assigned to anamnestic, personal data,
 and rapid test collection
- 296
 2. FFP2 or equivalent filtered mask, surgical cap, visor, gloves and waterproof disposable
 297
 297 gown for personnel assigned to NPS collection and venous sample collection.

Moreover, we decided to position a plexiglass barrier with a specifically-designed hole through which the rapid test is performed. This guarantees additional safety for personnel assigned to rapid testing and data collection, without the discomfort of wearing PPEs. The same barrier was proposed to the nurses assigned to venous blood sampling, but was not implemented based on previous negative experiences with this method of blood collection through the plexiglass barrier.

Rooms and surfaces will be sanitized three times a day using 0.1-0.5% sodium hypochlorite solution for large surfaces eg. floors, walls, chairs; and 62-71% alcohol for small surfaces (whenever there is biological contamination) and remaining instrumentation.

307 Sanitization will be carried out with disposable cloths or paper towels, to be suitably eliminated308 (biohazardous waste).

309 Sanitization of any medical devices (sphygmomanometer, pulse oximeter, etc.) will be carried310 out between each use.

311

312 Data management

313 Study data will initially be stored on a certified database of the i-Care platform, provided by 314 MEDISPA. Subsequently, an original database will be created, in collaboration with the 315 University of Milan Data Science Research Center, for data processing and analysis, according 316 to i-Care database data protection requirements, from which data transfer will take place.

317 Patient data will be traceable to a completely anonymous identification code (no data from 318 which patient identity could be derived will be recorded), thus only the doctor assigned to 319 patient data collection and, if required, subjects authorized by national privacy regulations will 320 be able to trace data back to the specific patient via the abovementioned identification code. In 321 any case, these subjects are bound by confidentiality according to current legislation. Patient 322 data will be made public only via scientific publications or conferences, and only in anonymous 323 aggregate form, always respecting current privacy laws (including but not limited to, "legge 324 privacy", 18/05/2018, n. 51 Legislative Decree; and the EU (GDPR) 2016/67910.

The protection of individuals will also be guaranteed according to the Oviedo Convention11 and the Declaration of Helsinki regarding ethical principles for medical research involving human subjects12, adopted by the World Medical Association in 1964.

- 329
- 330
- 331

332 LIST OF ABBREVIATIONS

SARS-CoV-2 severe acute respiratory s	yndrome coronavirus 2
--	-----------------------

- 334 COVID-19 COronaVirus Induced Disease 2019
- **rRT-PCR** real-time reverse transcription polymerase chain reaction
- 336 NPS nasopharyngeal swab
- **SISS** Sistema Informativo SocioSanitario (regional healthcare information system)
- 338 WHO World Health Organization
- **PPE** personal protective equipment

357 **BIBLIOGRAPHY**

- Total COVID-19 cases by province. In: COVID-19 in Italy Monitoring by the Civil
 Protection Department. 2020.
- 361 http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce47
 362 <u>8eaac82fe38d4138b1</u> Accessed 4 June 2020.
- 2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
- 364 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
- descriptive study. The Lancet. 2020;395:507–13
- 366 3. WHO Director-General's opening remarks at the media briefing on COVID-19 11
- 367 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening 368 remarks-at-the-media-briefing-on-covid-19---11-march-2020 Accessed 14 Apr 2020.
- 369 4. WHO | Coronavirus disease (COVID-2019) R&D. WHO. World Health Organization.
- 370 2020. http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/
- 371 Accessed 27 Mar 2020.
- 5. COVID-19 Report by ISS n. 11/2020 Reccomendations for the correct sampling,
- 373 conservation and analysis of COVID-19 oro/nasopharyngeal swabs. 2020.
- 374 http://www.iss.it/documents/20126/0/Rapporto+ISS+COVID- Accessed 14 Apr 2020.
- 3756. Machin D, Campbell M, Tan SB, and Tan SH. Sample Size Tables for Clinical
- 376 Studies. 3rd ed. Chichester, UK: Wiley-Blackwell; 2009.
- Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed.
 New York: John Wiley & Sons; 2003.
- 8. Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion:
- 380 Comparison of Seven Methods. In: Statistics in Medicine; 1998. p. 857-872.

381	9. Hajian-	Tilaki K. Sample size estimation in diagnostic test studies of biomedical
382	informa	tics. Journal of Biomedical Informatics. 2014;48:193-204.
383	10. Regulat	ion (EU) 2016/679 of the European Parliament and of the council of 27 April
384	2016 on	the protection of natural persons with regard to the processing of personal
385	data and	d on the free movement of such data, and repealing Directive 95/46/EC
386	(Genera	al Data Protection Regulation). In: EuroLex – Access to European Union law.
387	https://e	eur-lex.europa.eu/eli/reg/2016/679/oj Accessed 7 May 2020.
388	11. Conven	tion for the protection of Human Rights and Dignity of the Human Being with
389	regard to	o the Application of Biology and Medicine: Convention on Human Rights and
390	Biomed	icine. In Council of Europe Treaty Office. 1997.
391	https://v	www.coe.int/en/web/conventions/full-list/-/conventions/treaty/164 Accessed on
392	8 May 2	2020.
393	12. Declara	tion of Helsinki regarding ethical principles for medical research involving
394	human s	subjects. In World Medical Association. https://www.wma.net/policies-
395	post/wn	na-declaration-of-helsinki-ethical-principles-for-medical-research-involving-
396	human-	subjects/ Accessed 7 May 2020.
397		
398		
399		
400		
401		
402		
403		
404		
405		

DECLARATIONS

407	Ethics approval and consent to participate
408	The study have been performed in accordance with the Declaration of Helsinki and was
409	approved by the Ethics Committee of the University of Milan on the 21st of April 2020
410	(reference number 35/2020). Informed consent to participate in the study will be obtained in
411	written form from all participants, or their parent or legal guardian in case of minors.
412	
413	Consent for publication
414	Not applicable.
415	
416	Availability of data and materials
417	The datasets used and analysed during the current study are available from the corresponding
418	author on reasonable request.
419	
420	Competing interests
421	The authors declare that they have no competing interests.
422	
423	Funding
424	This study will be carried out with the non-conditioning contribution of CISOM, Fondazione
425	Rava, Armani C/O Unimi e Mediolanum C/O Fbf/Sacco.
426 427 428	Vittore Scolari received support from the LabEx DEEP (ANR-11-LABX-0044, ANR-10-IDEX-0001-02)
429	
430	
431	
	17

432 Authors' contributions

- 433 MG, GP, DB, AG and FC contributed to the conception and design of the protocol and revised
- 434 the manuscript;
- 435 EB and PB contributed to the design of the protocol, the acquisition, analysis and interpretation
- 436 of data, and revision of the work;
- 437 RR and VS contributed to the acquisition, analysis and interpretation of data;
- 438 CEG and SC drafted and substantially revised the work.
- 439 All authors declare to approve the submitted version and agree to be personally accountable for
- their contributions.
- 441

442 Acknowledgements

- 443 The authors would like to acknowledge the substantial contribution provided by Medispa
- 444 s.r.l., which contributed to the protocol by providing expertise, personnel and the informatic
- 445 platform.